Amgen Terminates Collaboration with TScan Therapeutics Over Crohn's Disease Research

TScan Therapeutics (TCRX) has lost its collaboration with Amgen, which focused on using TScan's target discovery platform to identify T-cell antigens in Crohn's disease.

The agreement was terminated by Amgen with a 90-day notice period, effective November 10, 2026. This means that TScan will not receive potential milestones and royalty payments from this collaboration unless Amgen or its affiliates continue to exploit product candidates created under the agreement.

TScan had received a $30 million non-refundable upfront payment in 2023 as part of the collaboration. The agreement also contemplated over $500 million in success-based milestone payments and tiered single-digit royalties on future product sales.